<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00669409</url>
  </required_header>
  <id_info>
    <org_study_id>A4091022</org_study_id>
    <nct_id>NCT00669409</nct_id>
  </id_info>
  <brief_title>A Phase 1/2A, Single Dose Study Of PF-04383119 In Japanese Patients With Moderate To Severe Pain From Osteoarthritis Of The Knee</brief_title>
  <official_title>A Phase 1/2A, Randomized, Placebo-Controlled, Double Blind, Dose-Escalation, Multicenter Study Of The Safety, Tolerability, Efficacy And Pharmacokinetics, Of A Single Intravenous Dose Of PF-04383119 In Japanese Patients With Moderate To Severe Pain From Osteoarthritis Of The Knee</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and tolerability of single IV doses of PF-04383119 in Japanese
      patients with moderate to severe pain from OA of the knee (Part I). To evaluate the
      preliminary analgesic efficacy of PF-04383119 in Japanese patients with moderate to severe
      pain from OA of the knee in comparison with placebo (Part I and Part II).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety assessments for the study include AE collection, vital signs, postural vital signs, weight, physical and neurological examinations, ECG, Hopkins Verbal Learning Test -Revised (HVLT-R™), and routine laboratory tests.</measure>
    <time_frame>120 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Western Ontario and McMaster Universities Arthritis (WOMAC 3.1™) scale.</measure>
    <time_frame>120 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>VAS for index knee pain during walking in the past 24 hours.</measure>
    <time_frame>120 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>VAS for index knee pain in the past 24 hours.</measure>
    <time_frame>120 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual analogue scale (VAS) for current index knee pain.</measure>
    <time_frame>120 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Following PK parameters will be determined from the plasma PF-04383119 concentration-time profiles by model-independent analysis: Cmax, Tmax, AUCinf, AUClast, V0, Vss, CL, MRT, and t1/2.</measure>
    <time_frame>120 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All patients exposed to PF-04383119 will be tested for development of anti-PF-04383119 antibodies.</measure>
    <time_frame>120 days</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">83</enrollment>
  <condition>Osteoarthritis, Knee</condition>
  <arm_group>
    <arm_group_label>10 mcg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>100 mcg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>200 mcg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>25 mcg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>50 mcg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-04383119 (tanezumab)</intervention_name>
    <description>single dose of 10 mcg/kg IV</description>
    <arm_group_label>10 mcg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-04383119 (tanezumab)</intervention_name>
    <description>single dose of 100 mcg/kg IV</description>
    <arm_group_label>100 mcg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-04383119 (tanezumab)</intervention_name>
    <description>single dose of 200 mcg/kg IV</description>
    <arm_group_label>200 mcg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-04383119 (tanezumab)</intervention_name>
    <description>single dose of 25 mcg/kg IV</description>
    <arm_group_label>25 mcg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-04383119 (tanezumab)</intervention_name>
    <description>single dose of 50 mcg/kg IV</description>
    <arm_group_label>50 mcg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-04383119 (tanezumab)</intervention_name>
    <description>single dose of Placebo IV</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Japanese Male or female, Age 35-65 (Part 1), Age 35-75 (Part 2)

          -  Diagnosis of osteoarthritis (OA) of the knee based on American College of Rheumatology
             criteria

          -  Knee pain, and radiographic evidence of knee OA (Kellgren-Lawrence x-ray grade ≥2)
             obtained within 1 year of enrollment

          -  At least one of the following: age &gt;50, morning stiffness &lt;30 minutes in duration,
             crepitus, and OA of the knee must involve the index tibiofemoral joint and must have
             present for at least 6 months

          -  Patients who meet at least one of the following: unwilling to take non-opiate pain
             medications, or for whom non-opiate pain medications have failed, or are candidates
             for or seeking invasive interventions such as intraarticular injections, knee
             arthroplasty, or total knee surgery

          -  Pain levels as required by the protocol at Screening and Baseline

        Exclusion Criteria:

          -  Diagnosis or history of RA, any inflammatory arthritis, gout, Paget's disease or any
             other disease that in the Investigator's opinion would interfere with the assessment
             of pain and other symptoms of OA

          -  Patients with regional pain syndromes suggestive of fibromyalgia or regional pain
             caused by lumbar or cervical compressions with radiculopathy or at risk of developing
             radiculopathy.

          -  Diagnosis or history of fibromyalgia

          -  Planned surgical procedure during the duration of the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Takasaki-shi</city>
        <state>Gunma-ken</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Fujisawa-shi</city>
        <state>Kanagawa-ken</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Yokohama-shi</city>
        <state>Kanagawa-ken</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Kawasaki-shi</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Beppu-shi</city>
        <state>Oita</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Fuchu City,</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Minato-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Shinagawa-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Shinjuku-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A4091022&amp;StudyName=A%20Phase%201/2A%2C%20Single%20Dose%20Study%20Of%20PF-04383119%20In%20Japanese%20Patients%20With%20Moderate%20To%20Severe%20Pain%20From%20Osteoarthritis%20Of%20The%20Knee%20</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>January 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 25, 2008</study_first_submitted>
  <study_first_submitted_qc>April 29, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 30, 2008</study_first_posted>
  <disposition_first_submitted>January 3, 2011</disposition_first_submitted>
  <disposition_first_submitted_qc>January 4, 2011</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">January 10, 2011</disposition_first_posted>
  <last_update_submitted>January 10, 2011</last_update_submitted>
  <last_update_submitted_qc>January 10, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 20, 2011</last_update_posted>
  <responsible_party>
    <name_title>Director, Clinical Trial Disclosure Group</name_title>
    <organization>Pfizer, Inc.</organization>
  </responsible_party>
  <keyword>monoclonal antibody</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

